Aerodiol: The efficacy and tolerability of intranasal estrogen administration. An overview;Aerodiol: Efficacia e tollerabilità degli estrogeni somministrati per via nasale. Compendio

Minerva Ginecologica

Volumn 55, Issue 3, 2003, Pages 189-200

  Genazzani, A R ^a,b   Cappagli, B ^a   Ciaponi, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Ospedali Riuniti Santa Chiara   (Italy)

Author keywords

Aerodiol, administration and dosage; Estrogens; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

BLOOD CLOTTING; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOMETRIUM ATROPHY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; LONG TERM CARE; MAMMARY GLAND; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SINGLE DRUG DOSE; TRANSDERMAL PATCH;

ADMINISTRATION, INTRANASAL; AEROSOLS; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 0242573041     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Hargrove JT, Eisenberg E. Menopause. Med Clin North Am 1995;79:1337-56.
2. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-41.
3. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
4. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113:95-103.
5. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;336:265-9.
6. Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int 1997;7Suppl 1:S3-7.
7. Kupperman HS, Blatt MHG, Wiebader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953; 13:688-703.
8. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998;316:1858-63.
9. Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III. Differential changes in bone mineral density of the appendicular and axial skeleton with aging. J Clin Invest 1981;67:328-35.
10. Gambacciani M, Spinetti A, De Simone L, Cappagli B, Maffei S, Taponeco F et al. The relative contribution of menopause and aging to postmenopausal vertebral osteopenia. J Clin Endocr Metab 1993;77:1148-52.
11. Nilas L, Christiansen C. The pathophysiology of peri- and postmenopausal bone loss. Br J Obstet Gynaecol 1989;96:580-7.
12. Gambacciani M, Spinetti A, Gallo R, Cappagli B, Ciaponi M, Piaggesi L et al. Cyclic-combined conjugate estrogens and dydrogesterone in the treatment of postmenopausal syndrome. Menopause 1995;21:19-25.
13. Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Manetti P, Piaggesi L et al. Longitudinal evaluation of premenopausal vertebral bone loss: effects of a low dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994;8:392-4.
14. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
15. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
16. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
17. Sherwin BB. Estrogenic effects on memory in women. Ann N Y Acad Sci 1994;743:213-31.
18. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12.
19. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
20. Hormone replacement therapy. Clinical Synthesis Panel on HRT. Lancet 1999;354:152-5.
21. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease and nondemented control subjects. Arch Neurol 51 1994;51:896-900.
22. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067-71.
23. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J. The metabolism of estradiol; oral compared to intravenous administration. J Steroid Biochem 1985;23(6A):1065-70.
24. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9 Suppl):18S-24S.
25. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
26. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991;73:275-80.
27. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lomo RA, et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6.
28. Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandeepol C. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 1995;22:207-18.
29. The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil Menopausal Stud 1993;38:5-11.
30. Jensen EV, Jacobsen HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18:387-414.
31. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134-9.
32. Greene GL, Gilna P, Waterfield M, Baker, A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231: 1150-4.
33. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
34. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, et al. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998;243:122-6.
35. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998;247:75-8.
36. Chu S, Fuller PJ. Identification of a splice variant of the rat estrogen receptor beta gene. Mol Cell Endocrinol 1997;132:195-9.
37. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 1998;26:3505-12.
38. Fuqua SA, Chamness GC, McGuire WL. Estrogen receptor mutations in breast cancer. J Cell Biochem 1993;51:135-9.
39. Friend KE, Resnick EM, Ang LW, Shupnik MA. Specific modulation of estrogen receptor mRNA isoforms in rat pituitary throughout the estrous cycle and in response to steroid hormones. Mol Cell Endocrinol 1997;131:147-55.
40. Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 1996;59:251-60.
41. Vignon F, Gompel A, Siromachkova M, Prébois C, Varin C, Rostène W. Effects of pulsed or continuous estradiol administration on proliferation of normal and tumoral human breast cells. Menopause 1999;6:362.
42. Jones NS, Quraishi S, Mason JD. The nasal delivery of systemic drugs. Int J Clin Pract 1997;51:308-11.
43. Nogradi M. Dimethyl-β-cyclodexstrin. Drugs Future 1984;9:577-8.
44. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-71.
45. Hermens WA, Belder CW, Merkus JM, Hooymans PM, Verhoef J, Merkus FW. Intranasal estradiol administration to oophorectomized women: Eur J Obstet Gynecol Reprod Biol 1991;40:35-41.
46. Lievertz RW. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987; 156:1289-93.
47. Scott RT Jr, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutancous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-64.
48. Carlstedt-Duke J. Cellular estrogen activity: implications for pulsed estrogen therapy. Maturitas 2001;38(Suppl 1):S7-S13.
49. Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 1999;353:1574-8.
50. Robinson JA, Spelsberg TC. Mode of action at the cellular level with specific reference to bone cells. In: Lindsay R, Dempster DW, Jordan VC, editors. Estrogens and antiestrogens. Philadelphy: Lippincott-Raven, 1997.p.43-62.
51. Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191-5.
52. Ho KK, Weissberger AJ. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 1992;7:821-7.
53. Dawson-Hughes B, Stern D, Goldman J, Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 1986;63:424-32.
54. Frohlander N, von Schoultz B. Growth hormone and somatomedin C during post-menopausal replacement therapy with oestrogen alone and in combination with an antioestrogen. Maturitas 1988;9:297-302.
55. Frantz AG, Rabkin MT. Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab 1965;25:1470-80.
56. Bellantoni MF, Harman SM, Cho DE, Blackman MR. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages. J Clin Endocrinol Metab 1991;72:172-8.
57. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-81.
58. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41.
59. Selby P, McGarrigle HH, Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin Endocrinol (Oxf) 1989;30:241-9.
60. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
61. Dooley M, Spencer CM, Ormrod D. Estradiol-intranasal: a review of its use in the management of menopause. Drugs 2001;61:2243-62.
62. Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart JM, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906-12.
63. Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C et al. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000; 182:545-52.
64. Pelissier C, de Kervasdoue A, Chuong VT, Maugis EL, de Mouillac F, Breil MH et al. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms. Maturitas 2001;37:181-9.
65. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods, BMJ 1996;313:36-9.
66. Doren M, Azzawi FA, Donnez J, Van der Mooren MJ, Villero J, Gompel A. Therapeutic value and long-term safety of pulsed estrogen therapy. Maturitas 2001;38 (Suppl 1):S23-30.
67. Christensen MS, Hagen C, Christiansen C, Transbol I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873-9.
68. Steingold KA, Laufer L, Chetkowski RJ, DeFazio JD, Matt DW, Meldrum DR et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
69. Bacchi-Modena A, Bolis P, Campagnoli C, De Cicco F, Meschia M, Pansini F et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27:285-92.
70. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170 (5 Pt 1):1213-23.
71. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5.
72. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26:219-26.
73. Gompel A, Bergeron C, Jondet M, Dhont M, Van der Mooren MJ, Toth KS et al. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year. Maturitas 2000;36:209-15.
74. Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41:29-39.
75. Pelissier C, de Kervasdoue A, Chuong VT, Maugis EL, de Mouillac F, Breil MH et al. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms. Maturitas 2001;37:181-9.
76. Panay N, Toth K, Pelissier C, Studd J. Dose-ranging studies of a novel intranasal estrogen replacement therapy. Maturitas 2001;38(Suppl 1):S15-22.
77. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168 (3 Pt 1):824-30.
78. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91-9.
79. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9.
80. Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
81. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care 1999;5:779-85.
82. Studd JW, McCarthy K, Zamblera D, Burger HG, Silberberg S, Wren B et al, Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995;22:105-14.
83. Erkkola R, Holma P, Jarvi T, Nummi S, Punnonen R, Raudaskoski T et al. Transdermal oestrogen replacement therapy in a Finnish population. Maturitas 1991;13:275-81.
84. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-8.
85. Frenkel Y, Kopernik G, Lazer S, Tugendreich D, Zmira N, Oettinger M et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
86. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin. Replacement Study follow-up (HERS II). JAMA 2002;288: 49-57.
87. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomised controlled trial. JAMA 2002;288:321-33.
88. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994;4:341-8.